AtCor Medical Pty Ltd's Comprehensive Scientific Review Highlights Importance of Noninvasive Central Blood Pressure Measurement
Published: May 11, 2010
ITASCA, IL--(Marketwire - May 11, 2010) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced that the peer-reviewed medical journal, Mayo Clinic Proceedings, has published a major review of scientific literature on noninvasive central blood pressure measurement in its May 2010 issue.
The article(1) cites three advantages of noninvasive central pressure measurement:
- Central pressures are a better predictor of cardiovascular outcome than conventional blood pressure measurements taken at the arm.
- Brachial blood pressure measurements taken at the arm do not accurately reflect central pressures.
- Medications affect central and brachial blood pressures differently.
The article reviews the physiological basis, methodology and history of noninvasive central pressure assessment and its application to patient management, summarizing articles published in medical literature from 1995-2009, and -- based on this accumulated evidence -- provides recommendations for clinical application of central blood pressure assessment.
Mayo Clinic video on noninvasively measuring central pressure released
The Mayo Clinic has also released a video featuring AtCor's SphygmoCor® technology, narrated by one of the article's authors, Dr. Jan Stepanek of the Mayo Clinic. The eight-minute video is available on the Mayo Clinic Proceedings website and on youtube.com (http://www.youtube.com/watch?v=OOK6T7tCUS4&feature=youtube_gdata). This shows noninvasive central pressure assessment in use at the Mayo Clinic, including case studies showing the benefits of the technology in patient management.
"We are delighted by this comprehensive review of the overwhelming body of accumulated evidence that supports the need to measure central blood pressure. This review from a world renowned centre clearly supports AtCor Medical's core objective of accelerating adoption of SphygmoCor in both clinical practice and pharmaceutical trials," said Duncan Ross, AtCor Medical President and CEO. "When identifying patients at cardiovascular risk and managing drug therapy, it is critically important to measure central pressures."
About AtCor Medical
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.
(1) Nelson, et al. Mayo Clin Proc. May 2010(85);5:460-472. Noninvasive Measurement of Central Vascular Pressures With Arterial Tonometry: Clinical Revival of the Pulse Pressure Waveform?
Abstract is available at http://www.mayoclinicproceedings.com/content/85/5/460.abstract
For further information, please contact:
AtCor Medical CEO
+1 (630) 228 8873
AtCor Medical Director of Marketing Services
+1 (630) 228 8875